Serum Level Of Heat Shock Protein 70 In Patients With Polycystic Ovarian Syndrome In Iraqi Women
DOI:
https://doi.org/10.46966/msjar.v4i4.161Keywords:
Polycystic Ovarian Syndromes, Heat Shock Proteins 70Abstract
Background: A common endocrine disease of fertile and postmenopausal woman was <polycystic ovarian syndromes> (PCO). Complex heterogeneous conditions, PCO has many different causes, consequences, and clinical symptoms. Uncertainty still exists regarding the pathogenic alterations of PCO. Recent study has looked into <heat shock proteins> (HSPs) functions as a cause of PCO.
Therefore, the aims of the study was determine whether HSP70 serum level differ among PCO women and women as healthy control. And confirmed HSP70 can help improve PCO predictive value. MATERIALS AND METHOD: This was a case control project compose of 90 woman their age (19-42 year), 60 of them PCO diagnosed, while another 30 who are healthy control from May 2022 to November 2022. Testosterones, follicle-stimulating hormones (FSH) and Luteinizing hormones (LH) were tested by specific enzyme linked immunofluorescence assays performed in VIDAS automatic. HSP70 was tested by ELISA method based on the principle of sandwich quantification (sunlong-china). RESULT: Mean HSP70 (ng/ml) was significantly higher in women with PCO in comparison with control group (P<0.05). In addition, compared with healthy groups, hormonal biomarkers such as testosterones, LH, FSH and BMI were found to be significantly elevated in the patients. CONCLUSIONS: Increase level of the HSP70 in women with PCO showed that HSP70 plays key roles in the pathological mechanism of PCOS.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Asma Ghalib, Taif Eimad Ahmed, Sahar Radhi Yasir , Dina Akeel salman
This work is licensed under a Creative Commons Attribution 4.0 International License.
In submitting the manuscript to the Medical Science Journal for Advance Research, the authors certify that:
- They are authorized by their co-authors to enter into these arrangements.
- The work described has not been formally published before, except in the form of an abstract or as part of a published lecture, review, thesis, or overlay journal.
- That it is not under consideration for publication elsewhere,
- The publication has been approved by the author(s) and by responsible authorities – tacitly or explicitly – of the institutes where the work has been carried out.
- They secure the right to reproduce any material that has already been published or copyrighted elsewhere.
- They agree to the following license and copyright agreement.
License and Copyright Agreement
Authors who publish with Medical Science Journal for Advance Research agree to the following terms:
- Authors retain copyright and grant the Medical Science Journal for Advance Research right of first publication with the work simultaneously licensed under Creative Commons Attribution License (CC BY 4.0) that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors can enter into separate, additional contractual arrangements for the non-exclusive distribution of the Medical Science Journal for Advance Research published version of the work (e.g., post it to an institutional repository or edit it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) before and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
